Type 1 diabetes is a chronic disease affecting an estimated 11-22 million people worldwide. It caused by the autoimmune destruction of the insulin-producing cells in the pancreas and results in the loss of the ability to maintain blood glucose homeostasis.
Currently, diabetics manage their condition by self-monitoring blood glucose, counting carbohydrates and taking insulin either with multiple daily injections or via insulin pump. Using these techniques, only about 25% of diabetics meet the standard for good glycemic control. Failure to achieve tight glycemic control is associated with a plethora of long-term complications including heart disease, kidney disease and neuropathy. Poor blood glucose control has also been shown to cause low energy, mood swings and cognitive disruptions on a daily basis.
Researchers at the CDT aim to make diabetes management easier and more effective through the development of artificial pancreas technology. By implementing advanced algorithms that use continuous glucose monitor data to automatically adjust insulin delivery, we have shown that time-in-range can be increased while simultaneously reducing the occurrence of hypoglycemia.
If you or a loved one would like to participate in one of our clinical studies, please click here.